EN
TradingView
Ticker Trading Ideas Educational Ideas Scripts People
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Sign Out Upgrade Upgrade now 30-day Free Trial Start free trial Upgrade plan Pay nothing extra Upgrade early
Markets US Stocks Health Technology Biotechnology

CATABASIS PHARMACEUTICALS INC
CATB NASDAQ

CATB
CATABASIS PHARMACEUTICALS INC NASDAQ
Trade now
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Trade now
Overview
Ideas Technicals

CATB Stock Chart

Ideas

Videos only
Long | CATB
CATB
, 1D
Long
CATB: Long | CATB

NASDAQ:CATB Possible Scenario: LONG Evidence: Price Action This is my idea and could be wrong 100%.

$CATB Catabasis Pharma $3.60 Potential Day Trade Target
CATB
, 1D
Long
CATB: $CATB Catabasis Pharma $3.60 Potential Day Trade Target

Some very bullish action pre market Indicators bullish Major Gap above with little to no price resistance

$CATB is gonna fall today
CATB
, 15 Short
CATB: $CATB is gonna fall today

Pupm&Dump trading strategy idea. $CATB is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,05; stop-loss — $2,42; take-profit — $1,68; Do not view this idea as a recommendation for trading or...

CATB
CATB
, D
CATB: CATB

TEST

CATB - Expecting Phase 2 trial data 04 October
CATB
, D
CATB: CATB - Expecting Phase 2 trial data 04 October

Could see high volatility given that this is there main product.

CATB 3min chart
CATB
, 15
CATB: CATB 3min chart

Higher Lows... Watch into PH

ready yo rumble
CATB
, 120
Long
CATB: ready yo rumble

Oversold and carwled enough .. ready to rumble

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —

Profile

Sector: Health Technology
Industry: Biotechnology
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out
Upgrade Upgrade now 30-day Free Trial Start free trial Upgrade plan Pay nothing extra Upgrade early